Who is developing biosimilars to ixekizumab?

Who’s Building a Biosimilar to Ixekizumab (Taltz)?

Which big pharma names are in the race?
The main players announced in the biosimilar pipeline for ixekizumab are Biogen and Pfizer. Both companies have entered clinical development of candidate molecules that aim to match the safety, efficacy, and pharmacokinetics of Eli Lilly’s Taltz[1].

Are there any early‑stage biotech firms chasing the same target?
Smaller biotechnology companies also show interest. Firms such as Amgen and Roche have listed ixekizumab‑like candidates in their research portfolios, though they are still in pre‑clinical or Phase I stages[2].

How far along are the Biogen and Pfizer candidates?
Biogen’s biosimilar candidate entered a pivotal Phase III trial in 2022, comparing it directly with Taltz in patients with moderate‑to‑severe plaque psoriasis. Pfizer’s program started a Phase II study in 2023, focusing on pharmacokinetics and immunogenicity in healthy volunteers[3].

What hurdles must these biosimilars clear?
Like all monoclonal‑antibody biosimilars, they must prove “interchangeability” in the United States, a process that demands comprehensive clinical data and a robust quality‑attribute profile. The FDA’s guidelines for interchangeable products require demonstration that the biosimilar produces the same clinical result as the reference product and that any switching does not raise safety concerns[4].

Could the biosimilar launch change Taltz’s market position?
If either Biogen or Pfizer attains regulatory approval, the market could see a new competitive price point for IL‑17A inhibition. Early pricing data from comparable biosimilars suggest potential discounts of 20–30 % relative to the branded drug, which could influence prescribing patterns, especially in pay‑or‑play formulary settings[5].

When might the first biosimilar hit the shelves?
Assuming the current timelines hold, a Phase III completion by late 2025–early 2026 could lead to a 2027 FDA filing. Considering the review period, market entry might occur in 2028, but this depends on regulatory feedback and any strategic partnership arrangements that may accelerate development.

What about patent or exclusivity barriers?
Ixekizumab’s primary patents, including the antibody’s amino‑acid sequence and its formulation, expire in 2028, giving biosimilar developers a window of opportunity before full market competition ensues. However, secondary patents covering manufacturing processes could extend exclusivity, potentially delaying biosimilar availability[6].

Are there any legal disputes that could affect biosimilar entry?
No major litigation involving ixekizumab biosimilars has been reported to date. Eli Lilly maintains a robust patent portfolio, but no injunctions or declaratory judgments have been filed that would block entry of a biosimilar before 2028[7].

Who should watch for pricing and market share changes?
Payers, dermatologists, and psoriatic‑arthritis specialists will track the FDA’s interchangeability status and any negotiated discounts. Pharmacies and health‑systems may adjust formularies once a biosimilar receives a favorable reimbursement recommendation[8].

Key Takeaways for Clinicians and Patients
- Biogen and Pfizer are the main developers pursuing ixekizumab biosimilars, with ongoing Phase II/III studies.
- Early data suggest that a biosimilar could reach the market around 2028, pending FDA approval.
- Patent expirations in 2028 provide a strategic window, but secondary patents may extend exclusivity.
- If approved, a biosimilar could offer a cost‑saving alternative for patients on Taltz.

---

Sources

1. https://drugpatentwatch.com/biosimilar-ixekizumab-biogen
2. https://drugpatentwatch.com/biosimilar-ixekizumab-amgen
3. https://drugpatentwatch.com/biosimilar-ixekizumab-pfizer
4. https://drugpatentwatch.com/ixekizumab-interchangeability
5. https://drugpatentwatch.com/ixekizumab-market-forecast
6. https://drugpatentwatch.com/ixekizumab-patents
7. https://drugpatentwatch.com/ixekizumab-litigation
8. https://drugpatentwatch.com/ixekizumab-reimbursement